Country: Australia
Bahasa: Inggeris
Sumber: Department of Health (Therapeutic Goods Administration)
Levetiracetam
Torrent Australasia Pty Ltd
Medicine Registered
1 LEVETIRACETAM GENERIC HEALTH LEVETIRACETAM TABLETS _ _ _ _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET Please read this leaflet carefully before you take this medicine. This leaflet answers some common questions about levetiracetam. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Sometimes new risks are found even when a medicine has been used for many years. Your doctor has weighed the expected benefits of you taking levetiracetam against the risks this medicine could have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT IS LEVETIRACETAM GENERIC HEALTH USED FOR Levetiracetam Generic Health is used for the control of epilepsy in adults and children. Epilepsy is a condition where you have repeated seizures (fits). There are many different types of seizures, ranging from mild to severe. Levetiracetam (the active ingredient in Levetiracetam Generic Health/) belongs to a group of medicines called antiepileptics. These medicines are thought to work by controlling brain chemicals which send signals to nerves so that seizures do not happen. Levetiracetam may be used Baca dokumen lengkap
PRODUCT INFORMATION LEVETIRACETAM GENERIC HEALTH LEVETIRACETAM TABLETS NAME OF THE MEDICINE Levetiracetam Chemical name: (S)-2-(2-oxopyrrolidin-1-yl)butanamide. Molecular Formula: C 8 H 14 N 2 O 2 Molecular weight: 170.2 CAS: 102767-28-2. DESCRIPTION Levetiracetam is a pure enantiomer. It is a white to off white powder with a faint odour and a bitter taste. It is very soluble in water (104 g/100 mL). It is freely soluble in chloroform (65.3 mg/100 mL) and in methanol (53.6 g/100mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane. PHARMACOLOGY The precise mechanism of action by which levetiracetam induces seizure protection is unknown, but appears unrelated to the mechanisms of current antiepileptic drugs. _In vitro _and _in vivo_ experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission. _In vitro _studies show that levetiracetam affects intraneuronal Ca 2+ levels by partial inhibition of N type Ca 2+ currents and by reducing the release of Ca 2+ from intraneuronal stores. In addition, it partially reverses the reductions in GABA and glycine gated currents induced by zinc and beta- carbolines. Furthermore, levetiracetam has been shown in _in vitro _studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their antiseizure protection in the mouse audiogenic model of epilepsy. Baca dokumen lengkap